STIMATE: A Protein Targeted for Drug Development (G375346)

Target Name: STIMATE

NCBI ID: G375346

STIMATE

STIMATE: A Protein Targeted for Drug Development

STIMATE (STIMA-HUMAN) is a protein that is expressed in various tissues of the human body, including the brain, pancreas, and muscle. It is a key regulator of insulin sensitivity and inflammation, and has been implicated in a number of diseases, including type 2 diabetes, obesity, and neurodegenerative disorders.

Recent studies have identified STIMATE as a potential drug target and biomarker for a variety of diseases, including type 2 diabetes, obesity, and neurodegenerative disorders. Its unique structure and regulation by multiple signaling pathways make it an attractive target for drug development.

One of the key signaling pathways that STIMATE is involved in is the TGF-β pathway. This pathway is involved in the regulation of cell growth, differentiation, and inflammation, and is a key regulator of stem cell proliferation. STIMATE has been shown to play a role in the regulation of TGF-β signaling in various tissues, including the brain and pancreas.

In addition to its role in TGF-β signaling, STIMATE is also involved in the regulation of several other signaling pathways, including the NF-kappa-B pathway and the PI3K/AKT pathway. These pathways are involved in the regulation of inflammation, inflammation-related pain, and cellular metabolism, and are key regulators of various diseases, including neurodegenerative disorders and cancer.

The identification of STIMATE as a potential drug target and biomarker has implications for the treatment of a variety of diseases. By inhibiting the activity of STIMATE, researchers may be able to improve insulin sensitivity, reduce inflammation, and alleviate symptoms of various diseases. Additionally, its unique structure and regulation by multiple signaling pathways make it an attractive target for drug development in a variety of settings, including neurodegenerative disorders, cancer, and obesity.

In conclusion, STIMATE is a protein that is expressed in various tissues of the human body and is involved in the regulation of multiple signaling pathways involved in the development and progression of various diseases. Its unique structure and regulation by multiple signaling pathways make it an attractive target for drug development, and its potential as a drug target and biomarker for a variety of diseases make it a promising area of research. Further studies are needed to fully understand its role in the regulation of various diseases and to develop effective treatments.

Protein Name: STIM Activating Enhancer

Functions: Acts as a regulator of store-operated Ca(2+) entry (SOCE) at junctional sites that connect the endoplasmic reticulum (ER) and plasma membrane (PM), called ER-plasma membrane (ER-PM) junction or cortical ER (PubMed:26322679, PubMed:26644574). SOCE is a Ca(2+) influx following depletion of intracellular Ca(2+) stores (PubMed:26322679). Acts by interacting with STIM1, promoting STIM1 conformational switch (PubMed:26322679). Involved in STIM1 relocalization to ER-PM junctions (PubMed:26644574). Contributes to the maintenance and reorganization of store-dependent ER-PM junctions (PubMed:26644574)

The "STIMATE Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about STIMATE comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets